Article Contents ::
- 1 Details About Generic Salt :: Hydralaz
- 2 Main Medicine Class:: Antihypertensive,Vasodilator
- 3 (high-DRAL-uh-zeen HIGH-droe-KLOR-ide) Apresoline, Apo-Hydralazine, Novo-Hylazin, Nu-Hydral Class: Antihypertensive/Vasodilator
- 4 Drugs Class ::
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
Details About Generic Salt :: Hydralaz
Main Medicine Class:: Antihypertensive,Vasodilator
(high-DRAL-uh-zeen HIGH-droe-KLOR-ide)
Apresoline, Apo-Hydralazine, Novo-Hylazin, Nu-Hydral
Class: Antihypertensive/Vasodilator
Drugs Class ::
Action Directly relaxes vascular smooth muscle to cause peripheral vasodilation, decreasing arterial BP and peripheral vascular resistance.
Indications for Drugs ::
Indications Treatment of essential hypertension (oral form). Treatment of severe essential hypertension (parenteral form). Unlabeled use(s): Reduction of overload in treatment of CHF, severe aortic insufficiency, and after valve replacement.
Drug Dose ::
Route/Dosage
Adjust individually. ADULTS: PO Begin with 10 mg qid for 2 to 4 days; then 25 mg qid for 3 to 5 days; then 50 mg qid (maximum 300 mg/day). IV/IM 20 to 40 mg repeated prn. CHILDREN: PO 0.75 mg/kg/day in 4 divided doses initially; increase gradually over 3 to 4 wk to maximum of 7.5 mg/kg/day or 200 mg/day. IV/IM 0.1 to 0.2 mg/kg/dose q 4 to 6 hr prn.
Contraindication ::
Contraindications Coronary artery disease; mitral valvular rheumatic heart disease.
Drug Precautions ::
Precautions
Pregnancy: Category C. Lactation: Excreted in breast milk. Children: Safety and efficacy have not been established by controlled clinical trials, but there is experience with its use. Lupus erythematosus: Drug may produce clinical picture similar to that with systemic lupus erythematosus (eg, arthralgia, dermatoses, fever, splenomegaly), including glomerulonephritis, when > 50 mg/day is given for long periods. Symptoms usually reverse when drug is discontinued, but treatment may be required. Renal impairment: Use drug with caution in patients with advanced renal damage. Tartrazine sensitivity: Some of these products contain tartrazine, which can cause allergic-type reactions in susceptible individuals, especially those who have aspirin hypersensitivity.
PATIENT CARE CONSIDERATIONS |
|
Drug Side Effects ::
Adverse Reactions
CV: Palpitations; tachycardia; angina pectoris; edema. CNS: Headache; peripheral neuritis with paresthesias, numbness and tingling; dizziness; tremors; depression; disorientation; anxiety. EENT: Lacrimation; conjunctivitis. GI: Anorexia; nausea; vomiting; diarrhea; constipation. HEMA: Blood dyscrasias; decreased hemoglobin; decreased RBC; leukopenia; agranulocytosis. OTHER: Hypersensitivity (eg, rash, urticaria, pruritus, fever, chills, arthralgia, eosinophilia); systemic lupus erythematosus.
Drug Mode of Action ::
Action Directly relaxes vascular smooth muscle to cause peripheral vasodilation, decreasing arterial BP and peripheral vascular resistance.
Drug Interactions ::
Interactions
Beta-blockers: May increase effect of hydralazine or effect of beta-blockers. NSAIDs: Effects of hydralazine may be decreased.
Drug Assesment ::
Assessment/Interventions
- Obtain complete history, including drug history and any known allergies. Note use of other medications (particularly beta-blockers and NSAIDs), coronary artery disease, mitral valvular rheumatic heart disease, renal impairment, lupus erythematosus, pregnancy, lactation.
- Monitor BP prior to and frequently during IV administration.
- Monitor CBC and antinuclear antibody titer.
- Monitor for orthostatic hypotension.
- If decreased hemoglobin or RBC, leukopenia, agranulocytosis or purpura occur, report to health care provider.
- If symptoms of lupus erythematosus or positive antinuclear antibody titer occur, notify health care provider.
- If hypotension occurs during therapy, caution patient to sit or lie down (with head in low position). Discontinue drug and notify health care provider.
|
Drug Storage/Management ::
Administration/Storage
- Administer oral form of drug with food.
- Use parenteral form immediately after drawn into syringe.
- Parenteral solution discolors after contact with metal filter.
- Store at room temperature.
Drug Notes ::
Patient/Family Education
- Instruct patient to take medication with meals to enhance absorption.
- Caution patient to avoid abrupt discontinuation of drug to prevent sudden increase in BP.
- Encourage patient to make lifestyle changes: Weight reduction, sodium and alcohol restriction, discontinuance of smoking, regular exercise, and behavior modification.
- Advise patient to monitor BP and weight regularly.
- Instruct patient to report sudden weight gain caused by fluid retention.
- Advise patient to follow health care provider’s orders for monitoring of CBC and other laboratory values.
- Advise patient to avoid sudden changes in position or very hot baths to avoid orthostatic hypotension.
- Caution patient not to take otc medications without consulting health care provider.
- Instruct patient to report these symptoms to health care provider: Prolonged tiredness, muscle or joint pain, chest pain, fever, numbness or tingling of hands or feet, rash.
- Explain that drug may cause drowsiness and to use caution when driving or performing other tasks requiring mental alertness.